Menu
FDA DECISION ·
Veppanu
vepdegestrant · Arvinas Operations
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with ER-positive, HER2-negative advanced or metastatic breast cancer and an ESR1 mutation detected by an FDA-authorized test, after progression on at least one endocrine therapy line.
LAMPGEN ANALYSIS
Why it matters
This brings an estrogen receptor-targeting protein degrader into ESR1-mutated breast cancer after endocrine progression. VERITAC-2 included a biomarker-defined subgroup within a broader enrolled population.
What research teams should watch
Record the molecular result, preceding endocrine regimen and progression date. Keep the approved subgroup visible when translating trial data into screening criteria.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
ESR1-selected advanced or metastatic diseasePRIMARY RECORDS